

Short synthesis of stenusine and norstenusine, two spreading alkaloids from *Stenus* beetles (Coleoptera: Staphylinidae)

Thomas Gedig,^a Konrad Dettner^b and Karlheinz Seifert^{a,*}

^aLehrstuhl für Organische Chemie, NW II, Universität Bayreuth, D-95440 Bayreuth, Germany

^bLehrstuhl für Tierökologie II, Universität Bayreuth, D-95440 Bayreuth, Germany

Received 5 December 2006; revised 9 January 2007; accepted 14 January 2007

Available online 17 January 2007

Abstract—Each of the both spreading alkaloids stenusine and norstenusine could be synthesized starting from commercially available 3-picoline in a two-step synthesis in yields of 74% and 67% in gram scale. The stereoisomeric ratio of the synthesized (+)-stenusine is similar to that of stenusine from *Stenus comma*.

© 2007 Elsevier Ltd. All rights reserved.

1. Introduction

The rove beetle genus *Stenus* comprises 1990 species worldwide¹ and about 120 species in Central Europe. *Stenus comma* LeConte, the most common species of the genus, lives in sandy banks of ponds and sluggishly flowing rivers.² The beetle has no ability to swim, but during its hunting for its prey, it often falls into the water. In order to avoid drowning, the beetle releases a surface-active fluid from the pygidial glands. This fluid propels the beetle over the water with a speed up to 75 cm/s. The Schildknecht group found that stenusine exhibits a high spreading capacity.² The surface-active oil contains some other compounds such as 1,8-cineol, isopiperitenol and 6-methyl-5-hepten-2-one.³ Norstenusine⁴ and actinidine⁵ could be detected in other *Stenus* species. Actinidine shows a knock-down effect to other insects.

Our objectives are the determination of the repellent activity of stenusine and norstenusine against predators and the analysis of their surface activity. For these reasons we were interested in the synthesis of stenusine (**1**) and norstenusine (**2**) (Fig. 1).

Numerous preparations of stenusine have been developed. The enantioselective 12-step synthesis of Enders et al.⁶ started from 5-*tert*-butyldimethylsilyloxy-pentanol⁷ and gave (2'*S*,3*S*)- and (2'*S*,3*R*)-stenusine in total yields of 7.8% and 5.7%. By means of the both diastereomeric compounds, the ratio of the four stereoisomers (2'*R*,3*R*):(2'*S*,3*R*):(2'*S*,3*S*):(2'*R*,3*S*) of natural stenusine from *S. comma* could be




Figure 1. Stenusine (**1**) and norstenusine (**2**). The numbering of the N- and C-atoms of **1** and **2** is used for the NMR assignments.

determined by chiral GC: 13%:40%:43%:4%. These four stenusine isomers in a ratio of 9%:36%:43%:12% could also be obtained in a two-step biomimetic route with a yield of 26% starting from (*R*)-phenylglycinol and glutaraldehyde. Since the found ratio of stereoisomers is similar to that of natural stenusine from *S. comma*, the authors consider this as a confirmation of their hypothesis for the biosynthesis of stenusine.⁸

2. Results and discussion

As we could demonstrate other *Stenus* species show completely different stenusine stereoisomer ratios.⁹ Stenusine from *Stenus juno* possesses mainly (2'*R*,3*R*)-configuration (88%), whereas in *Stenus clavicornis*, *Stenus providus* and *Stenus bimaculatus* the (2'*S*,3*R*)-stereoisomer dominates (95%, 95%, 76%). For *Stenus fulvicornis* (2'*R*,3*S*)-stenusine was found as the main peak (90%). This shows that the biosynthesis of stenusine in other *Stenus* species than *S. comma* is highly enantio- and diastereoselective.

Although our synthesis of stenusine (**1**) is not based on a biomimetic route, it leads also to a stereoisomer ratio (2'*R*,3*R*):(2'*S*,3*R*):(2'*S*,3*S*):(2'*R*,3*S*) of 10%:29%:54%:7%, which is similar to the natural stenusine from *S. comma* (Fig. 2).

Keywords: Alkaloids; Asymmetric synthesis; Stenusine; *Stenus comma*; Staphylinidae.

* Corresponding author. Tel.: +49 0921 553396; fax: +49 0921 555358; e-mail: karlheinz.seifert@uni-bayreuth.de





Figure 2. Gas chromatogram of synthetic (left) and natural (right) stenusine (**1**) from *S. comma*, fused with silica capillary column (30 m, 0.25 mm ID), coated with 0.25 μm film of 0.4% heptakis(2,3-di-*O*-methyl-6-*O*-*tert*-butyldimethylsilyl) β -cyclodextrin (30%) in SE 52 (70%), carrier gas He, temperature program 60 $^{\circ}\text{C}$ (20 min isothermal), heating rate 2 $^{\circ}\text{C}/\text{min}$ to 200 $^{\circ}\text{C}$. Capillary column was self-prepared by D. Burkhardt and A. Mosandl, University of Frankfurt am Main.

The alkylation of the methyl group of 3-picoline (**3**) with (*R*)-2-bromobutane gives 82% yield with 66% ee (*S*)-3-(2'-methylbutyl)pyridine (**4**, 83%) and its (*R*)-enantiomer (**4**, 17%). This enantiomeric mixture reacts with ethyl iodide quantitatively to yield 1-ethyl-3-(2'-methylbutyl)pyridinium iodide (**5**). Reduction of **5** with NaBH_4 leads to 3,4-didehydrostenusine (**6**), which can be transformed by catalytic hydrogenation under normal pressure to four stereoisomers of stenusine (**1**). Catalytic hydrogenation of the pyridinium salt **5** at a hydrogen pressure of 10 bar gives 90% yield of the four stenusine isomers (**1**) and so the total yield over three steps starting from 3-picoline is 74% (Scheme 1).



Scheme 1. Synthesis of stenusine (**1**). Reagents and conditions: (a) LDA, THF, 0 $^{\circ}\text{C}$; (*R*)-2-bromobutane, THF, -78 $^{\circ}\text{C}$ to room temperature, 82%; (b) EtI, 90 $^{\circ}\text{C}$, 0.5 h, 100%; (c) NaBH_4 , MeOH/THF 2:1, -78 $^{\circ}\text{C}$ to room temperature, 96%; (d) H_2 (normal pressure), Pd/C, EtOAc, 35 $^{\circ}\text{C}$, 89%; (e) H_2 (10 bar), Pd/C, MeOH, room temperature, 16 h, 90%; (f) H_2 (20 bar), Pd/C, MeCHO, MeCOOH, 30 $^{\circ}\text{C}$, 24 h, 90%.

A further distinct improvement of the stenusine synthesis can be achieved by reaction of 3-(2'-methylbutyl)pyridine (**4**) with acetaldehyde under hydrogenating conditions. In this way **1** can be synthesized in two steps with 74% yield (Scheme 1).

The use of 2-bromopropane instead of (*R*)-2-bromobutane for the alkylation of 3-picoline methyl group gives 81% yield of 3-isopropylpyridine (**7**), which can be transformed in an analogous way as **4** with comparable yields in a three- or two-step reaction sequence to racemic norstenusine (**2**).

In order to demonstrate that stenusine (**1**) and norstenusine (**2**) are surface-active compounds, the surface tension was determined by means of the pendant drop tensiometry at 22 $^{\circ}\text{C}$. At a concentration of 0.125% of stenusine (**1**) or norstenusine (**2**) in an aqueous 0.1 M phosphate buffer, a surface tension of about 60 mN/m is observed (Fig. 3). Even at 0.05% stenusine concentration, a distinct lowering of the surface tension (65 mN/m) compared with water (72.8 mN/m) is observed. Sodium phosphate is as electrolyte surface inactive, so that the comparison of the surface tensions of stenusine (**1**) and norstenusine (**2**) in phosphate buffer with water is justified.

3. Experimental

3.1. Alkylation of 3-picoline (**3**)

3.1.1. Alkylation with (*R*)-2-bromobutane. A mixture of diisopropylamine (7.4 ml, 5.3 g, 52.5 mmol) in abs THF (120 ml) under argon is cooled to -30 $^{\circ}\text{C}$. To this mixture *n*-BuLi (21.0 ml, 2.5 M, 52.5 mmol) is added under stirring. After 1 h, 3-picoline (**3**, 4.8 ml, 4.7 g, 50 mmol) is slowly added and stirring is continued for 1 h at 0 $^{\circ}\text{C}$. (*R*)-2-Bromobutane (5.5 ml, 6.9 g, 50 mmol) is slowly added to the deep brown solution at -78 $^{\circ}\text{C}$ and the mixture is warmed to room temperature overnight. The reaction mixture is diluted with half saturated NH_4Cl solution, the organic phase is separated and the aqueous phase extracted three times with EtOAc. The combined organic phases are washed with saturated NaCl solution and dried with MgSO_4 . After filtration through Celite[®] and removing the solvent under vacuum, 3-(2'-methylbutyl)pyridine (**4**, 6.95 g, 47 mmol, 93%, crude product) is obtained. Distillation gives **4** (6.10 g, 40.9 mmol, 82%) as colourless oil. $[\alpha]_D^{23} +5.8$ (*c* 2.10, CHCl_3); $^1\text{H NMR}$ (300 MHz, CDCl_3): δ (ppm)=8.38 (dd, 1H, 6-H, $^3J_{6,5}=4.9$ Hz, $^4J_{6,4}=1.6$ Hz), 8.36 (br s, 1H, 2-H), 7.40 (dd, 1H, 4-H, $^3J_{4,5}=7.8$ Hz, $^4J_{4,6}=1.6$ Hz), 7.14 (ddd, 1H, 5-H, $^3J_{5,4}=7.8$ Hz, $^3J_{5,6}=4.9$ Hz, $^5J_{5,2}=1.0$ Hz), 2.58 (dd, 1H, 7-H_a, $^2J_{7a,7b}=13.7$ Hz, $^3J_{7a,8}=6.1$ Hz), 2.32 (dd, 1H, 7-H_b, $^2J_{7a,7b}=13.7$ Hz, $^3J_{7b,8}=8.2$ Hz), 1.59 (m_c, 1H, 8-H), 1.34, 1.14 (2m_c, 2H, 9-H), 0.87 (dd, 3H, 10-H, $^3J_{10,9}=7.5$ Hz), 0.80 (d, 3H, 11-H, $^3J_{11,8}=6.6$ Hz); $^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ (ppm)=150.3 (2-C), 146.9 (6-C), 136.5 (3-C),




Figure 3. Surface tension of stenusine (1) (left) and norstenusine (2) (right) in 0.1 M phosphate buffer (pH 6) determined by means of pendant drop tensiometry at 22 °C.

136.2 (4-C), 122.9 (5-C), 40.0 (7-C), 36.2 (8-C), 28.8 (9-C), 18.5 (11-C), 11.1 (10-C); GC-MS, EI⁺: *m/z* (%)=150 (4) [M+H⁺], 149 (28) [M⁺], 118 (5), 93 (100) [C₆H₇N⁺], 92 (18), 65 (13), 57 (21) [C₄H₅⁺], 41 (20) [C₃H₃⁺]; HRMS (70 eV): 149.1204 [C₁₀H₁₅N⁺] (calcd 149.1205), 93.0579 [C₆H₇N⁺] (calcd 93.0579), 57.0704 [C₄H₅⁺] (calcd 57.0704).

3.1.2. Alkylation with isopropyl bromide. 3-Picoline (**3**, 4.8 ml, 4.7 g, 50 mmol), isopropyl bromide (4.7 ml, 6.15 g, 50 mmol). Yield of 3-isobutylpyridine (**7**): 6.26 g, 46.3 mmol, 93%, crude product; after distillation 5.48 g, 40.5 mmol, 81%. ¹H NMR (300 MHz, CDCl₃): δ (ppm)=8.28 (dd, 1H, 6-H, ³J_{6,5}=4.9 Hz, ⁴J_{6,4}=1.7 Hz), 8.26 (br s, 1H, 2-H), 7.30 (dd, 1H, 4-H, ³J_{4,5}=7.8 Hz, ⁴J_{4,6}=1.7 Hz), 7.04 (dd, 1H, 5-H, ³J_{5,4}=7.8 Hz, ³J_{5,6}=4.9 Hz), 2.32 (d, 2H, 7-H, ³J_{7,8}=7.5 Hz), 1.72 (m_c, 1H, 8-H), 0.73 (d, 6H, 9-H, 10-H, ³J_{8,9/10}=6.8 Hz); ¹³C NMR (75 MHz, CDCl₃): δ (ppm)=150.2 (2-C), 146.9 (6-C), 136.3 (3-C), 136.0 (4-C), 122.7 (5-C), 42.0 (7-C), 29.7 (8-C), 21.8 (9-C, 10-C); GC-MS, EI⁺: *m/z* (%)=135 (41) [M⁺], 118 (3), 93 (100) [C₆H₇N⁺], 92 (27), 66 (6), 65 (14), 51 (4), 43 (20), 41 (10) [C₃H₃⁺], 39 (13); HRMS (70 eV): 135.1048 [C₉H₁₃N⁺] (calcd 135.1048), 93.0578 [C₆H₇N⁺] (calcd 93.0579), 41.0391 [C₃H₃⁺] (calcd 41.0391).

3.2. N-Ethylation

3.2.1. N-Ethylation of 3-(2'-methylbutyl)pyridine (4) with ethyl iodide. Under argon, ethyl iodide (2.90 ml, 5.57 g, 35.7 mmol) is added to 3-(2'-methylbutyl)pyridine (**4**, 3.55 g, 23.8 mmol) and heated for 30 min under reflux (temperature of the oil bath 90 °C). The surplus ethyl iodide is distilled off under vacuum and 1-ethyl-3-(2'-methylbutyl)pyridinium iodide (**5**) is obtained in quantitative yield (7.27 g, 23.8 mmol, 100%) as viscous pale yellow oil. ¹H NMR (300 MHz, CDCl₃): δ (ppm)=9.23 (br s, 1H, 2-H), 9.13 (d, 1H, 6-H, ³J_{6,5}=6.1 Hz), 8.10 (d, 1H, 4-H, ³J_{4,5}=8.0 Hz), 7.91 (dd, 1H, 5-H, ³J_{5,6}=6.1 Hz, ³J_{5,4}=8.0 Hz), 4.79 (q, 2H, 12-H, ³J_{12,13}=7.4 Hz), 2.73 (dd, 1H, 7-H_a, ²J_{7a,7b}=13.8 Hz, ³J_{7a,8}=6.1 Hz), 2.50 (dd, 1H, 7-H_b, ²J_{7b,7a}=13.8 Hz, ³J_{7b,8}=8.3 Hz), 1.61 (m_c, 1H, 8-H), 1.52 (t, 3H, 13-H,

³J_{13,12}=7.4 Hz), 1.18, 1.01 (2m_c, je 1H, 9-H), 0.69 (dd, 3H, 10-H, ³J_{10,9}=7.3 Hz), 0.66 (d, 3H, 11-H, ³J_{11,8}=6.5 Hz); ¹³C NMR (75 MHz, CDCl₃): δ (ppm)=145.1 (2-C), 143.5 (6-C), 142.7 (3-C), 141.5 (4-C), 127.5 (5-C), 56.4 (12-C), 38.9 (7-C), 35.3 (8-C), 28.3 (9-C), 18.0 (11-C), 16.9 (13-C), 10.7 (10-C).

3.2.2. N-Ethylation of 3-isobutylpyridine (7) with ethyl iodide. 3-Isobutylpyridine (**7**, 3.92 g, 29.0 mmol), ethyl iodide (3.50 ml, 6.74 g, 43.2 mmol). Yield of 1-ethyl-3-isobutylpyridinium iodide (**8**): 8.44 g, 29.0 mmol, 100%, crude product. ¹H NMR (300 MHz, CDCl₃): δ (ppm)=9.03 (br s, 1H, 2-H), 8.99 (d, 1H, 6-H, ³J_{6,5}=6.1 Hz), 7.94 (d, 1H, 4-H, ³J_{4,5}=7.9 Hz), 7.80 (dd, 1H, 5-H, ³J_{5,6}=6.1 Hz, ³J_{5,4}=7.9 Hz), 4.63 (q, 2H, 11-H, ³J_{11,12}=7.2 Hz), 2.50 (d, 2H, 7-H, ³J_{7,8}=7.6 Hz), 1.76 (m_c, 1H, 8-H), 1.43 (t, 3H, 12-H, ³J_{12,11}=7.2 Hz), 0.72 (2d, 6H, 9-H, 10-H, ³J_{9/10,8}=6.7 Hz); ¹³C NMR (75 MHz, CDCl₃): δ (ppm)=144.6 (2-C), 144.5 (6-C), 142.8 (3-C), 142.3 (4-C), 127.7 (5-C), 56.8 (11-C), 41.0 (7-C), 29.3 (8-C), 21.6 (9-C, 10-C), 16.9 (12-C).

3.3. Partial reduction of the pyridinium salts to the tetrahydropyridines

3.3.1. Reduction of 1-ethyl-3-(2'-methylbutyl)pyridinium iodide (5). Compound **5** (3.51 g, 11.5 mmol) is dissolved under argon in MeOH/THF (2:1, 120 ml) and cooled to -78 °C. NaBH₄ (1.30 g, 34.5 mmol) is added, the mixture is stirred for 20 min at -78 °C, warmed to room temperature overnight and cooled again to -78 °C. NaBH₄ (0.87 g, 23 mmol) is added and the reaction mixture is warmed to room temperature for 5 h. To stop the reaction, 2 N HCl (125 ml, 250 mmol) is added and stirred for 1 h at room temperature. To prevent the oxidation of iodide by air, a small amount of Na₂SO₃ is added, the volume of the reaction mixture is reduced to about 1/5 and 2 N KOH (about 100 ml) is added (pH>10). The mixture is extracted three times with EtOAc (50 ml), the combined organic layers are washed with saturated NaCl solution and dried with MgSO₄. After filtration through Celite® and removing the solvent crude

product (2.09 g, 11.5 mmol, 100%), from which **5** (91 mg, 0.30 mmol, 3%) is separated as viscous oil. The resulting 1-ethyl-3-(2'-methylbutyl)-1,2,5,6-tetrahydropyridine (**6**, 3,4-didehydrostenusine, 2.00 g, 11.0 mmol, 96%) is not further purified. ¹H NMR (300 MHz, CDCl₃): δ (ppm)=5.35 (m_c, 1H, 4-H), 2.74 (m_c, 2H, 2-H), 2.41 (m_c, 2H, 6-H), 2.40 (q, 2H, 12-H, ³J_{12,13}=7.3 Hz), 2.10 (m_c, 2H, 5-H), 1.89 (dd, 1H, 7-H_a, ²J_{7a,7b}=13.6, ³J_{7a,8}=6.3 Hz), 1.65 (dd, 1H, 7-H_b, ²J_{7b,7a}=13.6, ³J_{7b,8}=8.2 Hz), 1.40 (m_c, 1H, 8-H), 1.30, 1.02 (2m_c, 2H, 9-H), 1.06 (t, 3H, 13-H, ³J_{13,12}=7.3 Hz), 0.80 (dd, 3H, 10-H, ³J_{10,9a}=³J_{10,9b}=7.5 Hz), 0.76 (d, 3H, 11-H, ³J_{11,8}=6.2 Hz); ¹³C NMR (75 MHz, CDCl₃): δ (ppm)=135.0 (3-C), 120.1 (4-C), 55.5 (2-C), 52.2 (12-C), 49.7 (6-C), 43.3 (7-C), 32.4 (8-C), 29.3 (9-C), 26.0 (5-C), 19.0 (11-C), 12.2 (13-C), 11.3 (10-C); GC-MS, EI⁺: *m/z* (%)=181 (17) [M⁺], 180 (7) [M⁺-H], 166 (19) [M⁺-CH₃], 152 (3) [M⁺-C₂H₅], 124 (100) [M⁺-C₄H₉], 110 (35) [M⁺-C₅H₁₁], 96 (7) [C₆H₁₀N⁺], 82 (4) [C₅H₈N⁺], 68 (13) [C₅H₈⁺], 56 (7) [C₃H₆N⁺], 42 (12) [C₂H₄N⁺], 41 (11); HRMS (70 eV): 181.1831 [C₁₂H₂₃N⁺] (calcd 181.1831), 166.1596 [C₁₁H₂₀N⁺] (calcd 166.1596), 124.1126 [C₈H₁₄N⁺] (calcd 124.1126), 110.0970 [C₇H₁₂N⁺] (calcd 110.0970), 68.0628 [C₅H₈⁺] (calcd 68.0626).

3.3.2. Reduction of 1-ethyl-3-isobutylpyridinium iodide (8). 1-Ethyl-3-isobutylpyridinium iodide (**8**, 4.22 g, 14.5 mmol). Yield of 1-ethyl-3-isobutyl-1,2,5,6-tetrahydropyridine (**9**, 3,4-didehydrostenusine): 2.27 g, 13.6 mmol, 94%, crude product. ¹H NMR (300 MHz, CDCl₃): δ (ppm)=5.30 (m_c, 1H, 4-H), 2.70 (m_c, 2H, 2-H), 2.36 (m_c, 2H, 6-H), 2.36 (q, 2H, 11-H, ³J_{11,12}=7.3 Hz), 2.06 (m_c, 2H, 5-H), 1.70 (d, 2H, 7-H, ³J_{7,8}=6.8 Hz), 1.60 (m_c, 1H, 8-H), 1.01 (t, 3H, 12-H, ³J_{12,11}=7.3 Hz), 0.76 (d, 6H, 9-H, 10-H, ³J_{9/10,8}=6.5 Hz); ¹³C NMR (75 MHz, CDCl₃): δ (ppm)=135.0 (3-C), 119.9 (4-C), 55.3 (2-C), 52.0 (11-C), 49.6 (6-C), 45.2 (7-C), 26.0 (8-C), 25.9 (5-C), 22.3 (9-C, 10-C), 12.1 (12-C); GC-MS, EI⁺: *m/z* (%)=167 (32) [M⁺], 166 (23) [M⁺-H], 152 (11) [M⁺-CH₃], 136 (3) [M⁺-CH₂CH₃], 124 (100) [M⁺-C₃H₇], 122 (9), 110 (83) [M⁺-CH₃-C₃H₆], 108 (13), 95 (23) [C₇H₁₁⁺], 81 (13), 68 (33) [C₄H₆N⁺], 67 (18), 58 (12), 56 (7) [C₃H₆N⁺], 55 (9), 42 (34) [C₂H₄N⁺], 41 (23), 39 (8).

3.4. Catalytic hydrogenation of the tetrahydropyridines

3.4.1. Hydrogenation of 3,4-didehydrostenusine (6). Compound **6** (2.00 g, 11.0 mmol) is dissolved in EtOAc (30 ml) and palladium on charcoal (10%, 585 mg, 0.55 mmol, 5 mol %) is added under argon. After four evacuations and fillings with hydrogen, the mixture is heated to 35 °C and stirred until the appropriate amount of hydrogen (250 ml) is consumed. The reaction mixture is filtered through Celite[®], the solvent is removed and the crude product (1.97 g, 10.7 mmol, 98%) is purified by column chromatography on silica gel with EtOAc as solvent to yield stenusine (**1**, 1.79 g, 9.8 mmol, 89%) as a colourless oil.

3.4.2. Hydrogenation of 3,4-didehydrostenusine (9). 3,4-Didehydrostenusine (**9**, 4.54 g, 27.2 mmol). Yield of 1-ethyl-3-isobutylpiperidine (**2**, norstenusine): 4.47 g, 26.4 mmol, 97%, crude product; after distillation 3.64 g, 21.5 mmol, 79%.

3.5. Hydrogenation and N-ethylation of the 3-alkylpyridines

3.5.1. Hydrogenation and N-ethylation of 3-(2'-methylbutyl)pyridine (4). Since the acid amount is critical for a fast reaction the amount of 3-(2'-methylbutyl)pyridine (**4**, 6.95 g, 46.6 mmol) is divided into two parts and each of them (**4**, 3.47 g, 23.3 mmol) is dissolved in concentrated acetic acid (80 ml). After the addition of palladium on charcoal (10%, 620 mg, 0.58 mmol, 2.5 mol %) and acetaldehyde (2.0 ml, 1.54 g, 35.0 mmol), the mixture is hydrogenated for 24 h in an autoclave at a hydrogen pressure of 20 bar and 30 °C. The two reaction mixtures are combined, filtered through Celite[®] and evaporated under vacuum to a volume of about 20 ml. Solid KOH is added until pH value of 10 is reached. The mixture is extracted four times with EtOAc (100 ml), the organic layer is dried with MgSO₄, evaporated and the crude product (8.36 g, 45.6 mmol, 98%) is degassed (inhibition of foam formation) by cooling three times with liquid nitrogen and slow heating to room temperature under vacuum. Distillation gives stenusine (**1**, 7.70 g, 42.0 mmol, 90%) as colourless oil. Bp 75 °C (15 Torr); [α]_D²⁰+10.3 (c 2.01, CH₃OH); ¹H NMR (500 MHz, CDCl₃): δ (ppm)=2.83 (m_c, 2H, 6-H_a), 2.81 (m_c, 1H, 2-H_a, (2'*S*,3*S*)-diastereomer), 2.77 (m_c, 1H, 2-H_a, (2'*S*,3*R*)-diastereomer), 2.32 (m_c, 4H, 12-H), 1.71 (m_c, 2H, 6-H_b), 1.70 (m_c, 1H, 4-H_a, (2'*S*,3*R*)-diastereomer), 1.64 (m_c, 1H, 4-H_a, (2'*S*,3*S*)-diastereomer), 1.58 (m_c, 2H, 8-H), 1.56 (m_c, 2H, 5-H_a), 1.52 (m_c, 2H, 5-H_b), 1.42 (m_c, 1H, 2-H_b, (2'*S*,3*R*)-diastereomer), 1.40 (m_c, 1H, 2-H_b, (2'*S*,3*S*)-diastereomer), 1.33 (m_c, 2H, 3-H), 1.23 (m_c, 2H, 9-H_a), 1.07 (m_c, 2H, 7-H_a), 1.05 (m_c, 2H, 9-H_b), 1.00 (t, 6H, 13-H, ³J_{13,12}=7.3 Hz), 0.88 (m_c, 2H, 7-H_b), 0.78 (m_c, 12H, 11-H, 10-H), 0.77 (m_c, 1H, 4-H_b, (2'*S*,3*S*)-diastereomer), 0.73 (m_c, 1H, 4-H_b, (2'*S*,3*R*)-diastereomer); ¹³C NMR (125 MHz, CDCl₃): (2'*S*,3*S*)-diastereomer: δ (ppm)=60.3 (2-C), 53.8 (6-C), 52.8 (12-C), 42.1 (7-C), 33.5 (8-C), 31.9 (4-C), 31.1 (3-C), 29.5 (9-C), 25.6 (5-C), 19.4 (11-C), 12.0 (13-C), 11.1 (10-C); (2'*S*,3*R*)-diastereomer: δ (ppm)=61.0 (2-C), 53.8 (6-C), 52.8 (12-C), 41.8 (7-C), 33.6 (8-C), 31.1 (3-C), 31.0 (4-C), 29.9 (9-C), 25.5 (5-C), 19.2 (11-C), 12.0 (13-C), 11.2 (10-C); GC-MS, EI⁺: *m/z* (%)=183 (23) [M⁺], 182 (23) [M⁺-H], 168 (100) [M⁺-CH₃], 154 (14) [M⁺-C₂H₅], 126 (7) [M⁺-C₄H₉], 124 (9), 112 (10) [M⁺-C₅H₁₁], 110 (4), 98 (14) [M⁺-CH₃-C₅H₁₀], 96 (8), 85 (10) [C₅H₁₁N⁺], 84 (9) [C₅H₁₀N⁺], 72 (33) [C₄H₁₀N⁺], 58 (44) [C₃H₈N⁺], 57 (13) [C₄H₉⁺], 44 (5), 42 (10), 41 (11); HRMS (70 eV): 183.1987 [C₁₂H₂₅N⁺] (calcd 183.1987), 168.1752 [C₁₁H₂₂N⁺] (calcd 168.1752), 126.1283 [C₈H₁₆N⁺] (calcd 126.1283), 112.1126 [C₇H₁₄N⁺] (calcd 112.1126), 98.0969 [C₆H₁₂N⁺] (calcd 98.0970), 85.0892 [C₅H₁₁N⁺] (calcd 85.0892), 72.0813 [C₄H₁₀N⁺] (calcd 72.0813).

3.5.2. Hydrogenation and N-ethylation of 3-isobutylpyridine (7). 3-Isobutylpyridine (**7**, 6.26 g, 46.3 mmol) is divided into two parts and to each of them (**7**, 3.13 g, 23.1 mmol) acetaldehyde (2.0 ml, 1.54 g, 35.0 mmol) is added. Yield of 1-ethyl-3-isobutylpiperidine (**2**, norstenusine): 7.46 g, 44.0 mmol, 95%, crude product; after distillation 6.52 g, 38.5 mmol, 83%. Bp 69 °C (15 Torr); ¹H NMR (300 MHz, CDCl₃): δ (ppm)=2.83 (m_c, 1H, 6-H_a), 2.78 (m_c, 1H, 2-H_a), 2.31 (m_c, 2H, 11-H), 1.73 (m_c, 1H, 6-H_b), 1.66 (m_c, 1H, 4-H_a), 1.57 (m_c, 3H, 3-H, 5-H_a, 8-H), 1.48 (m_c, 1H, 5-H_b), 1.42 (dd, 1H, 2-H_b, ²J_{2b,2a}=³J_{2b,3}=10.8 Hz), 1.02 (t, 3H,

12-H, $^3J_{12,11}=7.3$ Hz), 0.97 (dd, 2H, 7-H, $^3J_{7,8}=^3J_{7,3}=6.8$ Hz), 0.81, 0.79 (2d, 6H, 9-H, 10-H, $^3J_{9,8}=^3J_{10,8}=6.3$ Hz), 0.74 (m_c, 1H, 4-H_b); ^{13}C NMR (75 MHz, CDCl_3): δ (ppm)=60.6 (2-C), 53.8 (6-C), 52.8 (11-C), 44.2 (7-C), 33.7 (3-C), 31.4 (4-C), 25.6 (5-C), 24.7 (8-C), 23.0 (9-C), 22.7 (10-C), 12.0 (12-C); GC-MS, EI⁺: m/z (%)=169 (32) [M⁺], 168 (31) [M⁺-H], 154 (100) [M⁺-CH₃], 140 (5) [M⁺-C₂H₅], 126 (8) [M⁺-C₃H₇], 112 (7) [M⁺-C₄H₉], 110 (5), 98 (14) [M⁺-CH₃-C₄H₈], 96 (8), 85 (11) [C₅H₁₁N⁺], 84 (10) [C₅H₁₀N⁺], 72 (39) [C₄H₁₀N⁺], 69 (10), 58 (73) [C₃H₈N⁺], 57 (17) [C₄H₉⁺], 55 (11), 42 (15) [C₂H₄N⁺], 41 (15); HRMS (70 eV): 169.1830 [C₁₁H₂₃N⁺] (calcd 169.1831), 154.1596 [C₁₀H₂₀N⁺] (calcd 154.1596), 126.1283 [C₈H₁₆N⁺] (calcd 126.1283), 112.1126 [C₇H₁₄N⁺] (calcd 112.1126), 98.0969 [C₆H₁₂N⁺] (calcd 98.0970).

Acknowledgements

Support of this research by the Deutsche Forschungsgemeinschaft (graduate college 678) is gratefully acknowledged.

We would like to thank Dipl.-Chem. D. Burkhardt and Prof. A. Mosandl from the University of Frankfurt am Main, Germany, for GC measurements at chiral phase.

References and notes

1. Herman, L. A. *Bull. Am. Mus. Nat. Hist.* **2001**, *265*, 2007–2439.
2. Schildknecht, H.; Krauß, D.; Connert, J.; Essenbreis, H.; Orfanides, N. *Angew. Chem.* **1975**, *87*, 421–422.
3. Schildknecht, H. *Angew. Chem.* **1976**, *88*, 235–272.
4. Kohler, P. Dissertation, Ruprecht-Karl-Universität Heidelberg, 1979.
5. Dettner, K. *Biochem. Syst. Ecol.* **1993**, *21*, 143–162.
6. Enders, D.; Tiebes, J.; De Kimpe, N.; Keppens, M.; Stevens, C.; Smaghe, G.; Betz, O. *J. Org. Chem.* **1993**, *58*, 4881–4884.
7. Enders, D.; Tiebes, J. *Liebigs Ann. Chem.* **1993**, 173–177.
8. Poupon, E.; Kunesch, N.; Husson, H.-P. *Angew. Chem., Int. Ed.* **2000**, *39*, 1493–1495.
9. Lusebrink, I.; Burkhardt, D.; Gedig, T.; Dettner, K.; Seifert, K.; Mosandl, A. *Naturwissenschaften*, in press.